V mutations

Overview of attention for article published in Frontiers in Molecular Biosciences, January 2024

Altmetric Badge

Mentioned by

twitter: 1 X user

Readers on

mendeley: 3 Mendeley

So far, Altmetric has seen 1 X post from an account with 2,499 followers.

New Research: A computational examination of the therapeutic advantages of fourth-generation ALK inhibitors TPX-0131 and repotrectinib over third-generation lorlatinib for NSCLC with ALK F1174C/L/V mutations https://t.co/8SoRgwkzFG #MolBioSci

13 Jan 2024

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.